Search
for
Sort by
Research 781–810 of 1000+
- Why are men with premature alopecia at higher risk of benign prostatic hyperplasia? And what about prostate cancer?
- UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
- Iatrogenic Cushing's Syndrome in a Patient With Salt-Wasting Congenital Adrenal Hyperplasia (SWCAH)
- Nonclassic Congenital Adrenal Hyperplasia: An Overview
- Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
- First case of V281+I172N/V281L CYP21A2 genotype associated with congenital adrenal hyperplasia form. A case report from South Italy
- Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?
- Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
- The prognostic value of androgenetic alopecia and benign prostatic hyperplasia in men with COVID-19: a prospective multidisciplinaryobservational study of 766 patients from Turkey
- SARS-CoV-2 vaccination in androgen sensitive phenotypes – A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients
- Association of Androgenetic Alopecia with Benign Prostatic Hyperplasia: A Case Control Study
- One year cross-sectional study of association between androgenetic alopecia and benign prostatic hyperplasia in a tertiary care hospital
- 1748 IS ANDROGENETIC ALOPECIA ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA? ANALYSIS OF 907 PATIENTS
- Faculty Opinions recommendation of Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
- Faculty Opinions recommendation of Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
- Comorbidities in patients with androgenetic alopecia: cardiovascular risk factors and benign prostatic hyperplasia
- 409 ANDROGEN RECEPTOR GENE POLYMORPHISM (SNP RS6152) – ITS RELATIONSHIP TO ANDROGEN-SENSITIVE GENES EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA, CARCINOMA OF THE PROSTATE AND ANDROGENETIC ALOPECIA
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
- Endocrine control of benign prostatic hyperplasia
- The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
- Abstract 1835: Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3 (WHSC1L1)
- Medical management of benign prostatic hyperplasia
- Medico-Surgical Therapeutic Management of Benign Prostatic Hyperplasia
- Update on medical management of benign prostatic hyperplasia
- A case of finasteride-induced hyperplasia of mammary glands
- “Dark Cells” in Normal, Hyperplastic, and Promoter-Treated Mouse Epidermis Studied by Conventional and High-Voltage Electron Microscopy
- Control of testosterone 5alpha-reductase activity in the human hyperplastic prostate
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
- The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
- Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFα expression in transgenic mice